Europe Leukemia Therapeutics Market - 2024-2031

Report Overview

The Europe leukemia therapeutics market reached US$ 4.7 billion in 2023 and is expected to reach US$ 7.56 billion by 2031, growing at a CAGR of 6.3% during the forecast period 2024-2031.

Leukemia is a blood cancer that occurs when the bone marrow produces abnormal white blood cells, also called blasts or leukemia cells. These abnormal cells can't fight infections and prevent the bone marrow from producing healthy red blood cells and platelets. Leukemia can spread to the lymph nodes, bloodstream, brain, spinal cord, and other parts of the body. If it spreads to the brain, symptoms may include headaches, seizures, balance problems, or vision problems.

If it spreads to the lymph nodes in the chest, symptoms may include breathing problems and chest pain. For the treatment of lymphoma various therapies such as targeted therapy, chemotherapy, immunotherapy, CAR T cell therapy, stem cell transplantation, and radiation therapy are used depending upon the type of leukemia and condition of the leukemia.

Market Dynamics: Drivers

Increasing prevalence of leukemia

The demand for the leukemia therapeutics market is driven by multiple factors. For instance, according to the Global Cancer Observatory, in Germany the number of new cases of leukemia in 2022 are 15,108. The number of deaths caused due to leukemia are 9,378. The 5 year prevalence rate in Europe is 45,413. CML prevalence in France is estimated at 2.5 per 100,000 inhabitants before the 1980s, with a progression up to 6 by 2002.

Since 2002 this trend has increased further, with current and predicted prevalence reaching levels around 18 and 24 per 100,000 in 2018 and 2030 respectively. CML prevalence reaches 30 per 100,000 by 2050 when progression slows. Acute myeloid leukemia is the most common acute leukemia in adults and affects 5/100,000 inhabitants in Europe, i.e., more than 20,000 new cases each year. The five-year survival rate of 60-year-old patients with AML is is less than 10%.

Restraints

Factors such as high costs associated with the treatment and stringent regulatory requirements for the approval of new treatments are expected to hamper the market. For instance, according to the National Institute of Health, the cumulative drug cost for 1 year of alemtuzumab which is used in the treatment of chronic leukemia, is US$ 70,000. Higher costs of drugs which affect the drug affordability of many people are one of the aspects that acts as a restraint to the Europe leukemia therapeutics market.

Market Segment Analysis

The Europe leukemia therapeutics market is segmented based on cancer type, therapy, end-user, and region.

The targeted therapy accounted for approximately 42.8% of the Europe leukemia therapeutics market share

The targeted therapy segment is expected to hold the largest market share over the forecast period. In this segment, the development of government regulation, and rising funds for private manufacturers for clinical trials would drive this market.

Targeted therapy drugs are the first line of treatment for certain types of leukemia. These medicines find and target specific proteins or changes in cells that cause leukemia. Unlike chemotherapy (which affects healthy and diseased cells), targeted therapy focuses only on the cell changes that cause the cancer. The drugs cause minimal, if any, damage to healthy cells. There are different types of targeted therapy drugs for leukemia. The lab-made drugs can find specific substances in leukemia cells, such as proteins or genetic (DNA) changes. The drugs then damage or destroy the diseased cells.

For instance, in December 2023, Eli Lilly announced that U.S. Food and Drug Administration (FDA) gave a second approval for its drug Jaypirca, which is used to treat a form of blood cancer. The health regulator gave the new approval to the drug for the treatment of chronic lymphocytic leukemia (CLL). Jaypirca was first given accelerated approval by the FDA in January 2023 for the treatment of mantle cell lymphoma (MCL), a rare type of blood cancer that starts in white blood cells and spreads to other parts of the body.

Market Segmentation

By Cancer Type

Chronic Myeloid Leukemia

Acute Lymphocytic Leukemia

Acute Myeloid Leukemia

Chronic Lymphocytic Leukemia

Others

By Therapy

Targeted Therapy

Bosutinib

Venetoclax

Chemotherapy

Rituximab

Dasatinib

Immunotherapy

Ofatumumab

Brexucabtagene autoleucel

Others

By End-User

Hospitals and Clinics

Cancer Centers

Ambulatory Surgical Centers

Others

Market Competitive Landscape

The major players in the Europe leukemia therapeutics market include Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited, Novartis AG, Bristol-Myers Squibb, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, AstraZeneca, Abbott, Novo Nordisk A/S, and Pfizer Inc. among others.

Key Developments

In April 2024, Sanofi has moved its natural killer (NK) cell engager candidate SAR443579/IPH6101 to a Phase II trial evaluating the drug's use in treating a range of blood cancers. The trial will investigate the therapy's safety, pharmacokinetics, pharmacodynamics and anti-leukemic activity in various haematological malignancies.

Why Purchase the Report?

To visualize the Europe leukemia therapeutics market segmentation based on cancer type, therapy, and end-user, as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of Europe leukemia therapeutics market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping is available in Excel consisting of key products of all the major players.

The Europe leukemia therapeutics market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies